NEW YORK (GenomeWeb News) – Promethera Biosciences today announced a collaboration with EMD Millipore to develop "an improved ready-to-use microfluidic perfusion liver assay."

Promethera added that it and EMD Millipore, a division of Germany's Merck KGaA, are receiving €900,000 ($1.2 million) from the Belgian Walloon Region Biocluster and the Massachusetts Life Sciences Center to support development of the assay, which is being designed so that "more robust studies in pre-clinical toxicity and drug metabolism" can be achieved.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.